Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionSPGM - SPDR(R) Portfolio MSCI Global Stock Market ETF
Latest Disclosed Ownership5,573 shares
Latest Disclosed Value $ 137,987
SPGM - SPDR(R) Portfolio MSCI Global Stock Market ETF reports 8.78% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 28, 2026 - SPGM - SPDR(R) Portfolio MSCI Global Stock Market ETF filed a NPORT-P form disclosing ownership of 5,573 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $137,987 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 26, 2026 disclosing 5,123 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 8.78% during the quarter. The current value of the position is $175,494 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-28 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 5,573 450 8.78 138 15.13 0.0097
2026-02-26 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 5,123 225 4.59 120 23.96 0.0090
2025-11-26 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 4,898 270 5.83 96 -4.00 0.0077
2025-08-28 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 4,628 135 3.00 100 -7.41 0.0092
2025-05-28 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 4,493 525 13.23 109 31.71 0.0114
2025-02-27 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,968 -90 -2.22 83 2.50 0.0097
2024-11-25 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 4,058 210 5.46 81 35.59 0.0090
2024-08-28 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,848 45 1.18 60 -1.67 0.0075
2024-05-28 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,803 225 6.29 61 0.00 0.0078
2024-02-27 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,578 30 0.85 60 46.34 0.0089
2023-11-28 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,548 300 9.24 41 -4.65 0.0068
2023-08-28 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,248 -255 -7.28 44 -25.86 0.0075
2023-05-30 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,503 420 13.62 58 1.75 0.0097
2023-02-28 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,083 120 4.05 57 50.00 0.0116
2022-11-28 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,963 203 7.36 38 100.00 0.0087
2022-08-26 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,760 116 4.39 19 -9.52 0.0044
2022-05-27 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,644 -783 -22.85 22 -8.70 0.0044
2022-02-25 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,427 493 16.80 23 53.33 0.0034
2021-11-26 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,934 -174 -5.60 16 -11.76 0.0028
2021-08-27 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,108 116 3.88 18 30.77 0.0030
2021-05-28 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,992 58 1.98 14 44.44 0.0026
2021-02-26 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,934 290 10.97 10 28.57 0.0020
2020-11-19 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,644 0 0.00 8 -41.67 0.0020
2020-08-27 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,644 2,625 13,815.79 12 71.43 0.0033
2020-06-01 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 19 0 0.00 0 -100.00 0.0000
2020-02-28 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 19 -781 -97.62 0 -100.00 0.0000
2019-11-18 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 800 800 4 0.0025
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.